Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-06-24 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes references to press releases attached as exhibits, which are typical for 6-K filings. The document is short (1763 characters) and primarily announces the inclusion of press releases rather than containing detailed financial data or comprehensive reports. It does not contain full financial statements or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-06-24 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled 'Désignation des transactions sur actions propres' (Declaration of transactions on own shares) and contains detailed tables listing daily share repurchase transactions, including dates, volumes, and prices. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS), which covers reports of companies buying back their own shares.
2025-06-24 French
Communiqué de presse : Sarclisa recommandé pour approbation dans l’UE par le CHMP pour le traitement du myélome multiple nouvellement diagnostiqué chez les patients éligibles à une greffe
Regulatory Filings Classification · 95% confidence The document is titled "Communiqué de presse" (Press Release) and announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) of the EMA regarding the recommendation for approval of the drug Sarclisa. It details clinical trial results (GMMG-HD7) and includes quotes from management and contact information for press/investor relations. This format—a formal announcement of a significant corporate/regulatory event (drug approval recommendation) released to the public and media—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a specific, time-sensitive announcement, it fits best as an Earnings Release (ER) if it were quarterly results, but since it is a regulatory/clinical milestone announcement, it is most accurately classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses this format for all major news. Given the options, and that it is a press release announcing a major regulatory/clinical development rather than routine financial results, RNS (Regulatory Filings - general fallback) is appropriate, but ER (Earnings Release) is often used for major corporate news releases. However, since the content is purely about a regulatory recommendation and clinical data, and not quarterly financial figures, RNS is the safer fallback for non-standard announcements. Upon review, many companies issue press releases about regulatory milestones which are not strictly 'Earnings Releases'. Therefore, RNS (Regulatory Filings) is the most appropriate general category for this type of announcement that doesn't fit the other specific categories like DIV, CAP, or MANG.
2025-06-23 French
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the EU approval recommendation for the drug Sarclisa. This type of announcement, detailing key clinical trial results (GMMG-HD7 phase 3 study) and regulatory milestones, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on the immediate release of key financial/clinical news rather than a comprehensive periodic report (like 10-K or IR), 'ER' (Earnings Release) is the most appropriate classification, as regulatory/clinical updates often accompany or substitute for traditional earnings announcements in the pharma sector, focusing on performance drivers. It is not a full financial report (10-K, IR), a transcript (CT), or a proxy statement (DEF 14A/PSI). It is a direct announcement of a significant event/result.
2025-06-23 English
Communiqué de presse : Dupixent est approuvé aux États-Unis comme le seul médicament ciblé pour traiter les patients atteints de pemphigoïde bulleuse
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces the FDA approval of Dupixent for treating bullous pemphigoid (PB). It details the clinical trial results (ADEPT study), quotes executives, and provides background information on the drug and the companies (Sanofi and Regeneron). This format—a formal announcement of a significant corporate/product event, often released to the public and media—is characteristic of a general press release. Since there is no specific regulatory filing code (like 10-K, ER, or AR) explicitly mentioned, and it is not a short announcement pointing to a separate report (Rule 2 does not apply as the content is substantial), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it serves as a public disclosure of a material event.
2025-06-20 French
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Regulatory Filings Classification · 99% confidence The document is explicitly titled '# **Press Release**' and announces a significant event: the US FDA approval of Dupixent for bullous pemphigoid. It contains key financial/product highlights, quotes from management/stakeholders, and details about clinical trial data (ADEPT study). This structure is characteristic of an Earnings Release (ER) or a major corporate announcement. Since it is focused on the immediate release of a major product milestone (FDA approval) rather than a comprehensive periodic financial report (like 10-K or IR), 'Earnings Release' (ER) is the most appropriate classification for a major corporate news announcement of this nature, even if it's not strictly tied to a quarterly earnings period. It is a direct announcement of a material event.
2025-06-20 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.